U.S. Markets closed

Exelixis, Inc. (EXEL)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
23.78-0.29 (-1.20%)
At close: 4:00PM EDT
People also watch
ARRYCLDXIMGNINCYSGEN
Full screen
Previous Close24.07
Open24.11
Bid24.28 x 100
Ask24.50 x 200
Day's Range23.78 - 24.54
52 Week Range7.43 - 24.85
Volume31,692,494
Avg. Volume3,761,282
Market Cap6.96B
Beta2.89
PE Ratio (TTM)1,132.38
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone
    Investor's Business Daily11 hours ago

    Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone

    With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.

  • Roundtable: 1 Stock I Brag About Owning
    Motley Fool15 hours ago

    Roundtable: 1 Stock I Brag About Owning

    Here are three stocks that our analysts enjoy saying "I told you so" about.

  • Capital Cubeyesterday

    Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : June 22, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 50. Our analysis is based on comparing Exelixis, Inc. with the following peers – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson, ArQule, Inc., Pfizer Inc., AVEO Pharmaceuticals, Inc. and Curis, ... Read more (Read more...)